From: Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
Compounda | Dose | Frequency of Use | Multivariate ORb(95% CI) |
---|---|---|---|
Celecoxib | 200 mg | Daily | 0.17 (0.03–0.83) |
Rofecoxib | 25 mg | Daily | 0.36 (0.14–0.91) |
Aspirin | 325 mg | 2–3 weekly | 1.02 (0.30–3.57) |
>3 weekly | 0.39 (0.22–0.72) | ||
trend (p < 0.05) | |||
Ibuprofen | 200 mg | 2–3 weekly | 0.59 (0.21–1.67) |
>3 weekly | 0.28 (0.13–0.61) | ||
trend (p < 0.01) |